Information Letter on valproate: restrictions on use and introduction of the contraceptive programme
2020.02.26
Active substance: valproate
The marketing authorisation holders Aristo Pharma GmbH, Desitin Arzneimittel GmbH and Sanofi-Aventis Deutschland GmbH will again provide information about restrictions on use and the introduction of the pregnancy prevention programme for valproate containing drugs.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN